The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

No changes in protocol recommended for LUGANO and LUCIA clinical trials –– Masked safety data continues to show no safety signals, consistent ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

A wireless retinal implant called PRIMA is changing that reality by helping blind patients read and recognize faces again.

Rhythmic electrical activity in the retina (known as pathological oscillations) has been observed in several eye diseases, including congenital stationary night blindness (CSNB) and retinitis ...